

Armed Cell Therapeutics Appoints Willemijn Kremer as Founding Chief Executive Officer

Appointment positions the company to advance its armed CAR-T programs toward the clinic

Paul Stoffels, MD, continues as Chair of the Board of Directors

Brussels, Belgium, October 15, 2026, 07:00 CEST — Armed Cell Therapeutics BV ("Armed Cell"), a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer, today announced the appointment of Willemijn Kremer as founding Chief Executive Officer. Paul Stoffels, MD, who led the company as interim CEO, continues as Chair of the Board of Directors.

Armed Cell recently acquired a preclinical portfolio of multi-targeting, armed CAR-T programs from Lakefront Biotherapeutics (formerly Galapagos NV). Its two lead programs focus on non-Hodgkin lymphoma and small cell lung cancer. The company is headquartered in Belgium, with operations in the Netherlands, research and pre-clinical operations in Pittsburgh, USA, and early development activities in Europe, Asia, and the United States.

Paul Stoffels, MD, Chair of the Board of Directors, commented: "Willemijn combines a physician's view of patients with deep experience in cell therapy strategy and corporate development. Having worked closely with her for several years, I know she has the drive and the judgment to build Armed Cell Therapeutics into a leading cell therapy company."

Ms. Kremer commented: "I'm honored to become the founding CEO of Armed Cell Therapeutics. We start with differentiated science and have a strong team in place that knows these programs inside out. I look forward to working with them to bring our armed CAR-T programs to patients who need better options."

Background information on Ms. Kremer

Ms. Kremer brings a combination of medical training, strategy experience, and hands-on cell therapy leadership. She joins from Galapagos, where she was Vice President, Corporate Development for Cell Therapy and Chief of Staff, working extensively with Paul Stoffels and John Mellors, Armed Cell Therapeutics Chief Scientific Officer. Before Galapagos, Ms. Kremer worked at McKinsey & Company. Ms. Kremer trained as a medical doctor at Utrecht University and holds an MBA from INSEAD.

About Armed Cell Therapeutics

Armed Cell Therapeutics is a biotechnology company developing next-generation armed CAR-T therapies for cancer. Its lead programs focus on non-Hodgkin lymphoma, where relapse after current CAR-T therapy remains common, and small cell lung cancer, an aggressive tumor with few effective treatment options. The company is headquartered in Belgium, with operations in the Netherlands, research and pre-clinical operations in Pittsburgh, USA, and early development CAR-T cell therapy activities in Europe, Asia, and the United States. For more information, visit www.armedcelltx.com.

Contact

Media: Srikant (Sri) Ramaswami, media@armedcelltx.com